OBJECTIVE: To test whether estrogen receptor polymorphisms modify the effects of postmenopausal hormone therapy on biomarkers and on risk of coronary heart disease events, stroke, or venous thromboembolism. METHODS AND RESULTS: The design was a nested case-control study in the Women's Health Initiative trials of postmenopausal hormone therapy. The study included all cases in the first 4 years: 359 cases of coronary heart disease, 248 of stroke, and 217 of venous thromboembolism. Six estrogen receptor-α polymorphisms and 1 estrogen receptor-β polymorphism were genotyped; 8 biomarkers known to be affected by hormone therapy were measured at baseline and 1 year after randomization. The polymorphisms were not associated with risk of vascular events and did not modify the increased risks of coronary heart disease, stroke, or venous thromboembolism due to hormone therapy. However, a reduced response of plasmin-antiplasmin to hormone therapy was noted for estrogen receptor-1 IVS1 (intron number 1)-354 (interaction P<0.0001, corrected for multiple comparisons P=0.014) and estrogen receptor-1 IVS1-1415 (interaction P<0.0001, corrected P=0.014). CONCLUSIONS: Estrogen receptor polymorphisms reduce the effect of postmenopausal hormone therapy on plasmin-antiplasmin, a marker of coagulation and fibrinolysis. However, screening for estrogen receptor polymorphisms to identify women at less risk of adverse cardiovascular outcomes is not likely to be useful in making decisions about hormone therapy treatment.
OBJECTIVE: To test whether estrogen receptor polymorphisms modify the effects of postmenopausal hormone therapy on biomarkers and on risk of coronary heart disease events, stroke, or venous thromboembolism. METHODS AND RESULTS: The design was a nested case-control study in the Women's Health Initiative trials of postmenopausal hormone therapy. The study included all cases in the first 4 years: 359 cases of coronary heart disease, 248 of stroke, and 217 of venous thromboembolism. Six estrogen receptor-α polymorphisms and 1 estrogen receptor-β polymorphism were genotyped; 8 biomarkers known to be affected by hormone therapy were measured at baseline and 1 year after randomization. The polymorphisms were not associated with risk of vascular events and did not modify the increased risks of coronary heart disease, stroke, or venous thromboembolism due to hormone therapy. However, a reduced response of plasmin-antiplasmin to hormone therapy was noted for estrogen receptor-1 IVS1 (intron number 1)-354 (interaction P<0.0001, corrected for multiple comparisons P=0.014) and estrogen receptor-1 IVS1-1415 (interaction P<0.0001, corrected P=0.014). CONCLUSIONS:Estrogen receptor polymorphisms reduce the effect of postmenopausal hormone therapy on plasmin-antiplasmin, a marker of coagulation and fibrinolysis. However, screening for estrogen receptor polymorphisms to identify women at less risk of adverse cardiovascular outcomes is not likely to be useful in making decisions about hormone therapy treatment.
Authors: Werner Koch; Petra Hoppmann; Arne Pfeufer; Jakob C Mueller; Albert Schömig; Adnan Kastrati Journal: Circulation Date: 2005-10-04 Impact factor: 29.690
Authors: P A Sakkinen; E M Macy; P W Callas; E S Cornell; T E Hayes; L H Kuller; R P Tracy Journal: Am J Epidemiol Date: 1999-02-01 Impact factor: 4.897
Authors: Amanda M Shearman; Serkalem Demissie; L Adrienne Cupples; Inga Peter; Christopher H Schmid; Jose M Ordovas; Michael E Mendelsohn; David E Housman Journal: Hum Mol Genet Date: 2005-07-13 Impact factor: 6.150
Authors: David M Herrington; Timothy D Howard; K Bridget Brosnihan; Donald P McDonnell; Xiaolin Li; Gregory A Hawkins; David M Reboussin; Jianfeng Xu; Siqun L Zheng; Deborah A Meyers; Eugene R Bleecker Journal: Circulation Date: 2002-04-23 Impact factor: 29.690
Authors: Moniek P M de Maat; Jonna Skov Madsen; Bente Langdahl; Else Marie Bladbjerg; Charlotte Landbo Tofteng; Bo Abrahamsen; Lars Rejnmark; Kim Brixen; Kaare Christensen; Jørgen Jespersen; Søren Risom Kristensen Journal: Thromb Haemost Date: 2007-02 Impact factor: 5.249
Authors: Kathy L E Klos; Eric Boerwinkle; Robert E Ferrell; Stephen T Turner; Alanna C Morrison Journal: J Lipid Res Date: 2008-04-30 Impact factor: 5.922
Authors: Sylvia Wassertheil-Smoller; Susan L Hendrix; Marian Limacher; Gerardo Heiss; Charles Kooperberg; Alison Baird; Theodore Kotchen; J David Curb; Henry Black; Jacques E Rossouw; Aaron Aragaki; Monika Safford; Evan Stein; Somchai Laowattana; W Jerry Mysiw Journal: JAMA Date: 2003-05-28 Impact factor: 56.272
Authors: Michiel J Bos; Stephanie C E Schuit; Peter J Koudstaal; Albert Hofman; André G Uitterlinden; Monique M B Breteler Journal: Stroke Date: 2008-02-28 Impact factor: 7.914
Authors: Charles Kooperberg; Mary Cushman; Judith Hsia; Jennifer G Robinson; Aaron K Aragaki; John K Lynch; Alison E Baird; Karen C Johnson; Lewis H Kuller; Shirley A A Beresford; Beatriz Rodriguez Journal: PLoS Clin Trials Date: 2007-06-15
Authors: Jacques E Rossouw; Ross L Prentice; JoAnn E Manson; Aaron K Aragaki; Judith Hsia; Lisa W Martin; Lewis Kuller; Karen C Johnson; Charles Eaton; Rebecca Jackson; Maurizio Trevisan; Matthew Allison; Ron C Hoogeveen Journal: Circulation Date: 2012-08-29 Impact factor: 29.690
Authors: Virginia M Miller; Gregory D Jenkins; Joanna M Biernacka; John A Heit; Gordon S Huggins; Howard N Hodis; Matthew J Budoff; Rogerio A Lobo; Hugh S Taylor; JoAnn E Manson; Dennis M Black; Frederick Naftolin; S Mitchell Harman; Mariza de Andrade Journal: Physiol Genomics Date: 2015-10-27 Impact factor: 3.107
Authors: Rabe E Alhurani; C Anwar A Chahal; Ahmed T Ahmed; Essa A Mohamed; Virginia M Miller Journal: Clin Sci (Lond) Date: 2016-07-01 Impact factor: 6.124